CKM and sarcopenia: Thus, we designed and successfully applied AAV mediated muscle‐specific muscle creatine kinase (MCK) promoter‐driven NLS‐PGC1α4 in GAS muscle and alleviated aging‐associated sarcopenia and metabolic disorders, including adiposity, insulin resistance, and fatty liver.